多囊性肾病市场－全球产业规模、份额、趋势、机会、预测：按类型、治疗类型、最终用户、地区和竞争对手划分，2021-2031年

全球多囊性肾病变市场预计将从 2025 年的 6.1611 亿美元成长到 2031 年的 9.5723 亿美元，复合年增长率为 7.62%。

这个市场领域涵盖药物疗法、影像解决方案和基因检测服务，旨在治疗以形成充满液体的肾囊肿为特征的遗传性疾病。推动这一增长的主要因素是研究投入的大幅增加以及旨在延缓疾病进展的新疗法的快速研发。为了佐证这一趋势，多囊性肾病基金会报告称，2024年研究人员获得了1566万美元的主导医学研究计划（CDMRP）津贴，与上年度相比增长了347%。

另一方面，市场成长也面临许多障碍，例如缓解疾病药物的高昂成本以及现有疗法所需的严格安全监测通讯协定。监管机构通常要求对主要药物进行严格的风险评估，因为这些药物可能具有肝毒性，这限制了患者的用药途径，并阻碍了患者的用药依从性，最终阻碍了市场渗透。

市场驱动因素

推动全球多囊性肾病变 (PCD) 市场发展的最重要因素是创新疾病修正治疗的核准和商业性应用。随着医疗机构扩大使用靶向血管加压素 V2 受体拮抗剂来减缓常染色体显性多囊性肾病变 (ADPKD) 患者的囊肿形成，该领域的经济可行性显着提高。这项商业性成功凸显了该市场未来创新的潜力，并支持持续生产以满足不断增长的患者需求。例如，大冢控股株式会社在 2025 年 2 月发布的「2024 财年合併会计」中报告称，其药品销售额同比增长 17.1%。这一成长主要得益于其旗舰 ADPKD 治疗药物 Zinalk 的强劲全球销售。这项业绩凸显了对有效治疗方法的迫切需求，并促使大冢控股进一步拓展尚未开发的国际市场。

同时，强大的临床研发管线和对肾臟疾病研发的大量投资正在改变市场走向，将重点从症状治疗转向基因治疗。生物技术公司正在筹集大量资金，以支持针对疾病遗传因素的新一代寡核苷酸（例如微型RNA抑制剂）的临床试验。患者资金筹措倡议进一步强化了这项创新，加速了临床试验参与者的招募和数据收集。 2025年，多囊性肾病基金会宣布，ADPKD註册登记库的参与者已超过3,200人，为加速临床研究提供了至关重要的资料来源。这种对开发平臺的重视也体现在财务策略中；Regulus Therapeutics在2025年3月发布的「2024财年第四季及全年业绩」中表示，已拨出7,580万美元现金，用于推动其在研ADPKD治疗药物RGLS8429的临床开发。

市场挑战

严格的安全监测要求以及疾病修正治疗的高成本是限制全球多囊性肾病变 (PCKD) 市场商业性成长的主要阻碍因素。监管机构经常实施广泛的风险评估通讯协定以应对潜在的肝毒性，这造成了复杂的行政流程，扰乱了处方流程。这些后勤方面的挑战给医疗专业人员和保险公司带来了沉重的负担，常常导致核准延迟和药物目录覆盖范围有限。因此，由于遵守这些强制性安全计画的复杂性，已获已通过核准药物的推广应用受到阻碍，这不仅令肾臟病学界望而却步，也限制了现有治疗方法的市场覆盖范围。

鑑于专科疾病管理的需求日益增长，这些市场进入限制尤其严峻。根据多囊性肾病基金会（PKD Foundation）统计，其卓越中心计画在2024年服务了15,600名患者，与前一年相比，寻求专科临床护理的患者人数增加了23%。儘管患者数量有所增加，但由于严格的财务和监管壁垒，相当一部分有意接受治疗的患者无法开始或继续长期药物治疗，市场并未充分利用这一机会。

市场趋势

基于基因型的精准医疗正在从根本上改变市场动态，其核心在于优先考虑诊断准确性和个人化治疗，而非一般性管理。这一趋势的驱动力在于综合基因检测在临床肾臟病学中的应用日益广泛，从而能够早期发现疾病亚型并制定个性化的治疗策略。 Natera公司在2025年2月发布的2024年第四季财报电话会议上公布，当季总收入达4.76亿美元，较去年同期成长53%。这项财务成就反映了该公司先进的基因检测产品（包括肾臟疾病检测产品）的快速普及。

同时，新型非血管加压素路径调节剂的出现正在拓展治疗产品线，研发人员正努力缓解标准V2受体拮抗剂相关的耐受性问题。透过聚焦于AMPK活化等替代代谢通路，科学家希望在不引起严重利尿副作用的情况下保护肾功能。这一策略转变得到了持续研发活动的支持。例如，Poxel公司在2025年10月发布的「2024年全年报告」中宣布，其合併销售额为660万欧元。这笔资金将用于支持公司推进PXL770的研发，PXL770是全球第一个用于治疗多囊性肾病变的AMPK活化剂。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球多囊性肾病变市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（常染色体显性多囊性肾病变 (ADPKD)、常染色体隐性多囊性肾病变 (ARPKD) 及其他）
  • 治疗类型（诊断、药物/治疗）
  • 依最终使用者（医院/诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美多囊性肾病变市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲多囊性肾病变市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区多囊性肾病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲多囊性肾病市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲多囊性肾病变市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球多囊性肾病变市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Otsuka Pharmaceuticals Co. Ltd
• Camber Pharmaceuticals Inc.
• Apotex Corp
• Ascend Laboratories LLC
• Par Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd
• Merck KGA
• Accord Healthcare Inc.
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Polycystic Kidney Disease Market is projected to expand from USD 616.11 Million in 2025 to USD 957.23 Million by 2031, reflecting a CAGR of 7.62%. This market sector encompasses pharmacotherapies, diagnostic imaging solutions, and genetic testing services aimed at managing the inherited condition defined by the formation of fluid-filled kidney cysts. The primary engines of this growth are the substantial rise in research investment and the rapid advancement of new therapeutic candidates intended to slow disease progression. Highlighting this trend, the PKD Foundation reported in 2024 that researchers obtained $15.66 million in Congressionally Directed Medical Research Programs grants, marking a 347% surge in funding over the prior year.

Conversely, market growth confronts significant obstacles regarding the elevated expense of disease-modifying drugs and the strict safety monitoring protocols necessitated for current treatments. Regulatory authorities frequently require stringent risk evaluation measures for major medications due to the potential for liver toxicity, which can restrict patient access and hinder prescription adherence, ultimately curbing widespread market adoption.

Market Driver

The most significant force driving the Global Polycystic Kidney Disease Market is the approval and commercial uptake of innovative disease-modifying therapies. As healthcare providers increasingly utilize targeted vasopressin V2-receptor antagonists to retard cyst development in Autosomal Dominant Polycystic Kidney Disease (ADPKD), the sector's financial viability has grown substantially. This commercial success confirms the market potential for future innovations and supports continuous manufacturing to satisfy rising patient demand. For instance, Otsuka Holdings Co., Ltd. reported in its February 2025 'FY2024 Consolidated Financial Results' that pharmaceutical revenue climbed by 17.1% year-over-year, a rise largely driven by strong global sales of its primary ADPKD drug, Jynarque. This performance highlights the acute need for effective treatments and spurs further expansion into under-served international markets.

Simultaneously, a strong clinical pipeline and heavy investment in renal R&D are transforming the market's trajectory, moving the focus from treating symptoms to genetic modification. Biotech companies are raising significant funds to support trials for next-generation oligonucleotides, such as microRNA inhibitors, that address the disease's genetic roots. This innovation is bolstered by patient engagement initiatives that speed up trial recruitment and data gathering. In 2025, the PKD Foundation announced that its ADPKD Registry had grown to over 3,200 participants, offering a critical data source for expediting clinical research. The dedication to these pipelines is reflected in financial strategies; Regulus Therapeutics Inc. noted in its March 2025 'Fourth Quarter and Year-End 2024 Financial Results' that it held $75.8 million in cash specifically to fund the clinical progression of its investigational ADPKD therapy, RGLS8429.

Market Challenge

The stringent safety monitoring requirements and high costs linked to disease-modifying therapies present a major constraint on the commercial growth of the Global Polycystic Kidney Disease Market. Regulatory bodies frequently enforce extensive risk evaluation protocols to address potential liver toxicity, introducing a complex administrative layer that impedes the prescription workflow. These logistical challenges place a heavier burden on healthcare practitioners and insurance providers, frequently resulting in authorization delays and limited formulary inclusion. As a result, the adoption of approved medications is suppressed, because the complexity of adhering to these mandatory safety programs deters the general nephrology community, thereby narrowing the market reach of existing treatments.

This limitation on market access is particularly damaging considering the rising demand for specialized disease management. According to the PKD Foundation, its Centers of Excellence program attended to 15,600 patients in 2024, representing a 23% rise in individuals seeking specialized clinical care compared to the previous year. Despite this expanding patient population, the market cannot fully leverage the opportunity because rigorous financial and regulatory obstacles prevent a significant portion of these engaged patients from starting or sustaining long-term pharmacological therapy.

Market Trends

The move toward Genotype-Guided Precision Medicine is fundamentally altering market dynamics by emphasizing diagnostic precision and customized treatments over generalized management. This trend is fueled by the growing incorporation of comprehensive genetic panels into clinical nephrology, allowing for the early detection of disease subtypes and the creation of personalized care strategies. In its 'Q4 2024 Earnings Presentation' from February 2025, Natera, Inc. announced that total quarterly revenues jumped 53% year-over-year to $476 million, a financial achievement that reflects the rapid uptake of its advanced genetic testing products, including those used for renal disorders.

At the same time, the rise of Novel Non-Vasopressin Pathway Modulators is broadening the therapeutic pipeline as developers attempt to reduce the tolerability issues linked to standard V2-receptor antagonists. By focusing on alternate metabolic pathways like AMPK activation, scientists hope to maintain kidney function without causing severe aquaretic side effects. This strategic shift is backed by ongoing development work; for example, Poxel SA reported in its October 2025 'Financial Results for Full Year 2024' that it secured consolidated revenue of EUR 6.6 million, capital that supports its operational commitment to progressing PXL770, its first-in-class AMPK activator for polycystic kidney disease.

Key Market Players

• Otsuka Pharmaceuticals Co. Ltd
• Camber Pharmaceuticals Inc.
• Apotex Corp
• Ascend Laboratories LLC
• Par Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd
• Merck KGA
• Accord Healthcare Inc.
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

Report Scope

In this report, the Global Polycystic Kidney Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polycystic Kidney Disease Market, By Type

• Autosomal dominant polycystic kidney disease (ADPKD)
• Autosomal recessive polycystic kidney disease (ARPKD)
• Others

Polycystic Kidney Disease Market, By Treatment Type

• Diagnosis
• Drug/Therapy

Polycystic Kidney Disease Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Polycystic Kidney Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycystic Kidney Disease Market.

Available Customizations:

Global Polycystic Kidney Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Polycystic Kidney Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Autosomal dominant polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney disease (ARPKD), Others)
  • 5.2.2. By Treatment Type (Diagnosis, Drug/Therapy)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Polycystic Kidney Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Polycystic Kidney Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Polycystic Kidney Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Polycystic Kidney Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End User

7. Europe Polycystic Kidney Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Polycystic Kidney Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Polycystic Kidney Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Polycystic Kidney Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Polycystic Kidney Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Polycystic Kidney Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Polycystic Kidney Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Polycystic Kidney Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Polycystic Kidney Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Polycystic Kidney Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Polycystic Kidney Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Polycystic Kidney Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Polycystic Kidney Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Polycystic Kidney Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Polycystic Kidney Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Polycystic Kidney Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End User

10. South America Polycystic Kidney Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Polycystic Kidney Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Polycystic Kidney Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Polycystic Kidney Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Polycystic Kidney Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Pharmaceuticals Co. Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Camber Pharmaceuticals Inc.
• 15.3. Apotex Corp
• 15.4. Ascend Laboratories LLC
• 15.5. Par Pharmaceuticals Inc.
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Merck KGA
• 15.8. Accord Healthcare Inc.
• 15.9. Pfizer Inc.
• 15.10. PD-Rx Pharmaceuticals, Inc

16. Strategic Recommendations

17. About Us & Disclaimer